• Mutation; HGNC; HGNC:9884; RB1; Unexplicit; Ex2-6del; Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; HGNC:9884; RB1; Unexplicit; IVS20+1G>A; Zygosity=Heterozygous (from parent cell line).
  

PubMed=4018796; DOI=10.1007/BF00295364
Squire J.A., Gallie B.L., Phillips R.A.
A detailed analysis of chromosomal changes in heritable and non-heritable retinoblastoma.
Hum. Genet. 70:291-301(1985)

PubMed=2751270
Chan H.S.L., Canton M.D., Gallie B.L.
Chemosensitivity and multidrug resistance to antineoplastic drugs in retinoblastoma cell lines.
Anticancer Res. 9:469-474(1989)

PubMed=2917337; DOI=10.1016/0165-4608(89)90079-4
Horsthemke B., Greger V., Becher R., Passarge E.
Mechanism of i(6p) formation in retinoblastoma tumor cells.
Cancer Genet. Cytogenet. 37:95-102(1989)

PubMed=2090524; DOI=10.1111/j.1432-0436.1990.tb00479.x
Griegel S., Heise K., Kindler-Rohrborn A., Rajewsky M.F.
In vitro differentiation of human retinoblastoma cells into neuronal phenotypes.
Differentiation 45:250-257(1990)

PubMed=2365495; DOI=10.1002/ijc.2910460123
Griegel S., Hong C., Frotschl R., Hulser D.F., Greger V., Horsthemke B., Rajewsky M.F.
Newly established human retinoblastoma cell lines exhibit an 'immortalized' but not an invasive phenotype in vitro.
Int. J. Cancer 46:125-132(1990)

PubMed=1679230; DOI=10.3109/13816819109023085
Madreperla S.A., Bookstein R., Jones O.W., Lee W.-H.
Retinoblastoma cell lines Y79, RB355 and WERI-Rb27 are genetically related.
Ophthalmic Paediatr. Genet. 12:49-56(1991)

PubMed=1682862; DOI=10.1016/S0161-6420(91)32134-1
Chan H.S.L., Thorner P.S., Haddad G., Gallie B.L.
Multidrug-resistant phenotype in retinoblastoma correlates with P-glycoprotein expression.
Ophthalmology 98:1425-1431(1991)

PubMed=23498719; DOI=10.1016/S1470-2045(13)70045-7
Rushlow D.E., Mol B.M., Kennett J.Y., Yee S., Pajovic S., Theriault B.L., Prigoda-Lee N.L., Spencer C., Dimaras H., Corson T.W., Pang R., Massey C., Godbout R., Jiang Z., Zacksenhaus E., Paton K., Moll A.C., Houdayer C., Raizis A., Halliday W., Lam W.L., Boutros P.C., Lohmann D.R., Dorsman J.C., Gallie B.L.
Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies.
Lancet Oncol. 14:327-334(2013)

PubMed=25326674; DOI=10.1007/s00418-014-1285-z
Busch M.A., Philippeit C., Weise A., Dunker N.
Re-characterization of established human retinoblastoma cell lines.
Histochem. Cell Biol. 143:325-338(2015)

PubMed=29192327; DOI=10.3892/or.2017.6100; PMCID=PMC5783599
Busch M.A., Papior D., Stephan H., Dunker N.
Characterization of etoposide- and cisplatin-chemoresistant retinoblastoma cell lines.
Oncol. Rep. 39:160-172(2018)

PubMed=30584916; DOI=10.1016/j.yexcr.2018.12.018
Schwermer M., Hiber M., Dreesmann S., Rieb A., Theissen J., Herold T., Schramm A., Temming P., Steenpass L.
Comprehensive characterization of RB1 mutant and MYCN amplified retinoblastoma cell lines.
Exp. Cell Res. 375:92-99(2019)